Skip to content

Proto Labs PRLB Pre-tax stock-based compensation cost

Pre-tax stock-based compensation cost at other companies

OTT
Otter TailOTTR
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$139.3M+10.4%
Gross profit$63.6M+14.2%
Operating income$9.8M+117%
Net income$8.1M+125%
EPS (diluted)$0.33+120%

Balance sheet

See full
Cash & equivalents$124.0M+49.9%
Total debt$2.6M-16.6%
Total equity$683.1M+4.0%
Total assets$778.6M+5.6%

Cash flow

See full
Operating cash flow$17.5M-4.6%
CapEx$3.5M+181%
Free cash flow$14.0M-18.2%

Valuation

See full
Market cap$1.9B+59.7%

Profitability

See full
Gross margin44.9%+0.5pp
Operating margin5.6%+1.7pp
Net margin4.7%+1.6pp
FCF margin10.4%-3.1pp

Returns & leverage

See full
Return on equity3.8%+1.6pp
Debt / equity0.0×
Current ratio3.5×+0.4×

Where this comes from

Reported directly by Proto Labs in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Proto Labs’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Proto Labs's pre-tax stock-based compensation cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Proto Labs's pre-tax stock-based compensation cost?
Proto Labs (PRLB) reported pre-tax stock-based compensation cost of $3.2M in Q1 2026.
How has Proto Labs's pre-tax stock-based compensation cost changed year-over-year?
Proto Labs's pre-tax stock-based compensation cost decreased by 20.0% year-over-year, from $4M to $3.2M.
What is the long-term trend for Proto Labs's pre-tax stock-based compensation cost?
Over 4 years (2021 to 2025), Proto Labs's pre-tax stock-based compensation cost has grown at a -4.6% compound annual growth rate (CAGR), from $19.1M to $15.83M.